The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.
Most Patients With CML Can Continue Their Normal Lifestyle During Treatment curetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from curetoday.com Daily Mail and Mail on Sunday newspapers.
Organizations Can Help Patients with CML Face the 'Long Treatment Journey' curetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from curetoday.com Daily Mail and Mail on Sunday newspapers.
YANTAI, China, June 3, 2024 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center